

in vivo

- International Journal of Experimental and Clinical Pathophysiology and Drug Research
- Published bimonthly by the International Institute of Anticancer Research
- Available online with Stanford University HighWire Press

ISSN (print): 0258-851X; ISSN (online): 1791-7549

General Policy

- IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.
- One of the principal aims of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.
- IN VIVO supports: (a) the aims and the research programmes of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel and Fax: +30-22950-53389; e-mail: journals@iiar-anticancer.org

For more information about IN VIVO, IIAR and the conferences please visit the IIAR websites: www.iiar-anticancer.org and www.iiarjournals.org

Selection of Recent Articles

Repopulation of the Irradiation Damaged Lung with Bone Marrow-derived Cells. M.E. BERNARD, H. KIM, M.S. RAJAGOPALAN, B. STONE, U. SALIMI, J.-C. RWIGEMA, M.W. EPPERLY, H. SHEN, J.U.P. GOFF, D. FRANICOLA, T. DIXON, S. CAO, X. ZHANG, H. WANG, D.B. STOLZ, J.S. GREENBERGER (*Pittsburgh, PA, USA*)

15-Lipoxygenase-1 Induces Lipid Peroxidation and Apoptosis, and Improves Survival in Rat Malignant Glioma. H. VIITA, A. PACHOLSKA, F. AHMAD, J. TIETÄVÄINEN, J. NAARALA, A. HYVÄRINEN, T. WIRTH, S. YLÄ-HERTTUALA (*Kuopio; Joensuu, Finland*)

Identification of Four Isoforms of Aldolase B Down-regulated in Hepatocellular Carcinoma Tissues by Means of Two-dimensional Western Blotting. Y. WANG, Y. KURAMITSU, M. TAKASHIMA, Y. YOKOYAMA, N. IIZUKA, T. TAMESA, I. SAKAIDA, M. OKA, K. NAKAMURA (*Ube, Japan*)

Effects of Polo-like-kinase-1-inhibitor BI 2536 in Squamous Cell Carcinoma Cell lines of the Head and Neck- first In Vitro Results. J. WAGENBLAST, D. HIRTH, L. THRON, C. ARNOLDNER, M. DIENSTHUBER, T. STÖVER, M. HAMBEK (*Frankfurt am Main, Germany; Vienna, Austria*)

Expression Patterns and Potential Action of the Calcium Transport Genes Trpv5, Trpv6, Ncx1 and Pmca1b in the Canine Duodenum, Kidney and Uterus. J.-A. KIM, H. YANG, I. HWANG, E.-M. JUNG, K.-C. CHOI, E.-B. JEUNG (*Chungbuk, Republic of Korea*)

Association of IGF Axis Hormones with Waist-to-Hip Ratio Varies by Physical Activity. K.H. SCHMITZ, D. XIE, V. TEAL, R. BALLARD-BARBASH, D. BERRIGAN (*Philadelphia, PA; Bethesda, MD, USA*)

Post-operative Corticosterone Levels in Plasma and Feces of Mice Subjected to Permanent Catheterization and Automated Blood Sampling. R. SUNDBOM, K.R. JACOBSEN, O. KALLIOKOSKI, J. HAU, K.S.P. ABELSON (*Uppsala, Sweden; Copenhagen, Denmark*)

Familial Hodgkin's Lymphoma in Scandinavia. V. JÖNSSON, H. AWAN, E. NYQUIST, M. MAISENHÖLDER, T.B. JOHANNESSEN, B. LY, G.E. TJØNNFJORD (*Oslo, Norway*)

Repair of Postauricular Defects Using a New Technique: The Swallowtail Flap. C. MONARCA, M. MARUCCIA, F. PALUMBO, N. SCUDERI (*Rome, Italy*)

Adipocyte-derived Factor as a Modulator of Oxidative Estrogen Metabolism: Implications for Obesity and Estrogen-dependent Breast Cancer. H.L. BRADLOW, D.W. SEPKOVIC, N. TELANG, R. TIWARI (*New York, NY, USA*)

No Cytomegalovirus Detected in the Gastrointestinal Tract of Patients with Active Crohns Disease. M.T. AARNIO, J.P. BÖHM, K.P. NUORVA, R.I. PITKÄNEN, T.H. KUOPIO, M.E. VOUTILAINEN (*Jyväskylä, Finland*)

Colon Cancer Vaccines: An Update (Review). E. MERIKA, M.W. SAIF, A. KATZ, C. SYRIGOS, M. MORSE (*London, UK; Haven, CT; Durham, NC, USA; Athens, Greece*)

Animal Models of N-Methyl-N-Nitrosourea-induced Mammary Cancer and Retinal Degeneration with Special Emphasis on Therapeutic Trials (Review). A. TSUBURA, OY.-C. LAI, H. MIKI, T. SASAKI, N. UEHARA, T. YURI, K. YOSHIZAWA (*Moriguchi, Osaka, Japan*)

Canine Mammary Tumours as a Model to Study Human Breast Cancer: Most Recent Findings (Review). F.L. QUEIROGA, T. RAPOSO, M.I. CARVALHO, J. PRADA, I. PIRES (*Vila Real, Portugal*)

Metastatic Potential of Orthotopic and Heterotopic Models Imaged by GFP and RFP Protein (Review). V. BOBEK, K. KOLOSTOVA, D. PINTEROVA, M. BOUBELIK, R. GURLICH, R.M. HOFFMAN (*Prague, Czech Republic; San Diego, CA, USA*)

Serotonin Transporter Polymorphism in Major Depressive Disorder (MDD), Psychiatric Disorders, and in MDD in Response to Stressful Life Events: Causes and Treatment with Antidepressant (Review). A. DANIELE, R. DIVELLA, A. PARADISO, V. MATTIOLI, F. ROMITO, F. GIOTTA, P. CASAMASSIMA, M. QUARANTA (*Bari, Italy*)

In Vivo Research Using Early Life Stage Models (Review). R. SEABRA, N. BHOGAL (*Nottingham, UK*)

FREE SPECIMEN COPIES OF IN VIVO ARE AVAILABLE ON REQUEST

Instructions to Authors

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

Tables. Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.

Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts". Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.

References. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC-IUB", "Bergey's Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text. For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Ethical Policies and Standards. CGP agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human fetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice.):

1. To submit your article online please visit: IIAR-Submissions (<http://www.iar-anticancer.org/submissions/login.php>)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:

John G. Delinassios
International Institute of Anticancer Research (IIAR)
Editorial Office of ANTICANCER RESEARCH,
IN VIVO, CANCER GENOMICS and PROTEOMICS.
1st km Kapandritiou-Kalamou Road
P.O. Box 22, GR-19014 Kapandriti, Attiki
GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free-of-charge. Additional copies, PDF files, or/and Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2012 - International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitter in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

* Review: Improved Radiotherapy for Primary and Secondary Liver Cancer: Stereotactic Body Radiation Therapy. C. TAO, L.-X. YANG (<i>San Francisco, CA, USA</i>)	649
Assessment of Sexual Function in Patients with Cancer Undergoing Radiotherapy – A Single Centre Prospective Study. D. VOMVAS, G. ICONOMOU, E. SOUBASI, M. LEOTSINIDIS, H.P. KALOFONOS, S. BERATIS, D. KARDAMAKIS, K. ASSIMAKOPOULOS (<i>Patras, Greece</i>)	657
Significance of Surgical Treatment of Liver Metastases from Gastric Cancer. Y. MIKI, K. FUJITANI, M. HIRAO, Y. KUROKAWA, M. MANO, M. TSUJIE, A. MIYAMOTO, S. NAKAMORI, T. TSUJINAKA (<i>Osaka, Japan</i>).....	665
The mRNA Expression of <i>DAP3</i> in Human Breast Cancer: Correlation with Clinicopathological Parameters. U. WAZIR, W.G. JIANG, A.K. SHARMA, K. MOKBEL (<i>London; Cardiff, Wales, UK</i>)	671
Comparison of Vinorelbine plus Cisplatin and S-1 plus Cisplatin in Concurrent Chemoradiotherapeutic Regimens for Unresectable Stage III Non-small Cell Lung Cancer. T. SHUKUYA, T. TAKAHASHI, H. HARADA, H. AKAMATSU, C. SAKAGUCHI, H. IMAI, A. ONO, Y. NAKAMURA, A. TSUYA, H. KENMOTSU, T. NAITO, H. MURAKAMI, M. ENDO, K. TAKAHASHI, N. YAMAMOTO (<i>Shizuoka; Tokyo, Japan</i>).....	675
Comparison of Concurrent Chemoradiotherapy <i>versus</i> Induction Chemotherapy Followed by Radiation in Patients with Nasopharyngeal Carcinoma. M. KOMATSU, M. TSUKUDA, H. MATSUDA, C. HORIUCHI, T. TAGUCH, M. TAKAHASHI, G. NISHIMURA, M. MORI, T. NIHO, J. ISHITOYA, Y. SAKUMA, M. HIRAMA, O. SHIONO (<i>Yokohoma, Japan</i>)	681
Reported Intake of Selected Micronutrients and Risk of Colorectal Cancer: Results from a Large Population-based Case-control Study in Newfoundland, Labrador and Ontario, Canada. Z. SUN, Y. ZHU, P.P. WANG, B. ROEBOTHAN, JING ZHAO, JINHUI ZHAO, E. DICKS, M. COTTERCHIO, S. BUEHLER, P.T. CAMPBELL, J.R. MCLAUGHLIN, P.S. PARFREY (<i>St. John's, NL; Toronto, ON, Canada; Tianjin, PR China; Atlanta, GA, USA</i>)	687
Metastatic Renal Cell Carcinoma Treated Sequentially with Multiple VEGF Receptor-targeted Inhibitors – A Case Report. C. LINASSIER, D. CARMIER, P. COMBE, B.F. D'ARCIER, F. BRUYERE, B. NARCISO (<i>Tours, France</i>)	697
Complete Pathological Response after Sequential Therapy with Sunitinib and Radiotherapy for Metastatic Clear Cell Renal Carcinoma. G. VENTON, A. DUCOURNAU, E. GROSS, E. LECHEVALLIER, A. ROCHWERGER, G. CURVALE, J.-V. ZINK, S. SALAS, J.-L. DEVILLE (<i>Marseilles, France</i>)	701
Mini-laparotomy <i>versus</i> Vaginal Surgery for Class II-III Obese Patients with Early-stage Endometrial Cancer. M. FAMBRINI, A. PIERALLI, U. BITOSSI, K.L. ANDERSSON, G. SCARSELLI, L. LIVI, G. TADDEI, M. MARCHIONNI (<i>Florence, Italy</i>)	707
Errata	713
Book reviews	715
* Reviews (pages 397, 405, 649)	

The Effect of Radiotherapy on Implant-based Breast Reconstruction in the Setting of Skin-sparing Mastectomy: Clinical Series and Review of Complications. K. HUGHES, C. BROWN, V. PEREZ, J.W.C. TING, W.M. ROZEN, I.S. WHITAKER, R. KORENTAGER (<i>Kansas City, KS, USA; Parkville, VIC, Australia</i>)	553
The Expression of MAGE and SSX, and Correlation of COX2, VEGF, and Survivin in Colorectal Cancer. J. CHOI, H. CHANG (<i>Busan, South Korea</i>)	559
Determination of Chronic Inflammatory States in Cancer Patients Using Assay of Reactive Oxygen Species Production by Neutrophils. Y. SUZUKI, S. OHNO, R. OKUYAMA, A. ARUGA, M. YAMAMOTO, S. MIURA, H. YOSHIOKA, Y. MORI, K. SUZUKI (<i>Tokyo; Kanagawa; Saitama, Japan</i>)	565
Human Papilloma Virus, Herpes Simplex Virus and Epstein Barr Virus in Oral Squamous Cell Carcinoma from Eight Different Countries. J. JALOULI, M.M. JALOULI, D. SAPKOTA, S.O. IBRAHIM, P.-A. LARSSON, L. SAND (<i>Uppsala; Helsingborg, Sweden; Bergen, Norway</i>)	571
Pelvic Dysfunctions and Quality of Life after Nerve-sparing Radical Hysterectomy: A Multicenter Comparative Study. M. CECCARONI, G. ROVIGLIONE, E. SPAGNOLO, P. CASADIO, R. CLARIZIA, M. PEIRETTI, F. BRUNI, I. PETERS, G. ALETTI (<i>Verona; Bologna; Milan, Italy; Leiden, The Netherlands</i>)	581
Prognostic Value of Biomarkers Related to Drug Resistance in Patients with Advanced Epithelial Ovarian Cancer. H. KIM, K. KIM, J.H. NO, Y.-T. JEON, H.W. JEON, Y.-B. KIM (<i>Gyeonggi-Do; Seoul, Republic of Korea</i>).....	589
Treatment Evaluation of Metastatic Lymph Nodes after Concurrent Chemoradiotherapy in Patients with Head and Neck Squamous Cell Carcinoma. G. NISHIMURA, H. MATSUDA, T. TAGUCHI, M. TAKAHASHI, M. KOMATSU, D. SANO, N. SAKUMA, Y. ARAI, H. TAKAHASHI (<i>Yokohama, Japan</i>)	595
Impacts of Treatment Lines and Initiation Timing of Erlotinib for Advanced Non-small Cell Lung Cancer. T. AOKI, S. IGAWA, N. FURUYA, M. KATAGIRI, J. HISATA, S. TAJIRI, N. HAYAMA, M. MINESHITA, T. URANO, T. MIYAZAWA, N. MASUDA, T. ABE (<i>Kanagawa, Japan</i>)	601
A Retrospective Study of Chemotherapy with and without Pemetrexed in Malignant Pleural Mesothelioma. M. HIGASHIGUCHI, H. SUZUKI, T. HIRASHIMA, M. KOBAYASHI, S. GOYA, N. OKAMOTO, Y. MATSUURA, M. TAMIYA, N. MORISHITA, T. TSUMORI, I. KAWASE (<i>Osaka, Japan</i>)	609
Intermediate Oncological Outcomes of Percutaneous Radiofrequency Ablation for Small Renal Tumors: Initial Experience. Y. NITTA, T. TANAKA, K. MORIMOTO, T. MAKINO, N. NISHIKAWA, K. TASHIRO, T. NAGANUMA, T. IGUCHI, T. MATSUOKA, T. NAKATANI (<i>Osaka, Japan</i>)	615
Inflammation-based Prognostic Score for Hepatocellular Carcinoma Patients on Sorafenib Treatment. M. MORIMOTO, K. NUMATA, S. MORIYA, M. KONDO, A. NOZAKI, Y. MORIOKA, S. MAEDA, K. TANAKA (<i>Yokohama, Japan</i>).....	619
Detection of Human Papillomavirus Genotypes in Bronchial Cancer Using Sensitive Multimetrix Assay. K. SYRJÄNEN, M. SILVONIEMI, E. SALMINEN, T. VASANKARI, S. SYRJÄNEN (<i>Turku, Finland</i>)	625
Docetaxel in the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC): an Observational Study in a Single Institution. D. SCHALLIER, L. DECOSTER, J. BRAECKMAN, C. FONTAINE, J. DEGRÈVE (<i>Brussels, Belgium</i>).....	633
A Randomized Comparison of Modified Intermediate-dose Ara-C versus High-dose Ara-C in Post-remission Therapy for Acute Myeloid Leukemia. T. FUKUSHIMA, Y. URASAKI, M. YAMAGUCHI, M. UEDA, K. MORINAGA, T. HABA, T. SUGIYAMA, S. NAKAO, H. ORIGASA, H. UMEHARA, T. UEDA (<i>Ishikawa; Fukui; Toyama, Japan</i>)	643

Effect of PI3K/Akt Pathway Inhibition-Mediated G1 Arrest on Chemosensitization in Ovarian Cancer Cells. M. FEKETE, C. SANTISKULVONG, C. ENG, O. DORIGO (<i>Los Angeles, CA, USA</i>)	445
Preclinical Activity of the Novel Orally Bioavailable HSP90 Inhibitor NVP-HSP990 against Multiple Myeloma Cells. T. STÜHMER, K. ISKANDAROV, Z. GAO, T. BUMM, E. GRELLA, M.R. JENSEN, H. EINSELE, M. CHATTERJEE, R.C. BARGOU (<i>Würzburg, Germany; Emeryville, CA, USA; Basel, Switzerland</i>)	453
The Dual Kinase Inhibitor NVP-BEZ235 in Combination with Cytotoxic Drugs Exerts Anti-proliferative Activity towards Acute Lymphoblastic Leukemia Cells. C. SCHULT, M. DAHLHAUS, A. GLASS, K. FISCHER, S. LANGE, M. FREUND, C. JUNGHANSS (<i>Rostock, Germany</i>)	463
Evaluation of Breast Cancer Susceptibility Loci on 2q35, 3p24, 17q23 and <i>FGFR2</i> Genes in Taiwanese Women with Breast Cancer. C.-Y. LIN, C.-M. HO, D.-T. BAU, S.-F. YANG, S.-H. LIU, P.-H. LIN, T.-H. LIN, N. TIEN, M.-C. SHIH, J.-J. LU (<i>Taichung; Miaoli; Taoyuan, Taiwan, ROC</i>)	475
Caveolin-1 Attenuates Hydrogen Peroxide-induced Oxidative Damage to Lung Carcinoma Cells. W. SUCHAOIN, P. CHANVORACHOTE (<i>Bangkok, Thailand</i>)	483
C-reactive Protein is a Potential Prognostic Factor for Metastatic Gastric Cancer. T. SHIMURA, M. KITAGAWA, T. YAMADA, M. EBI, T. MIZOSHITA, S. TANIDA, H. KATAOKA, T. KAMIYA, T. JOH (<i>Nagoya, Japan</i>)	491
Involvement of MAP Kinases in the Cytotoxicity of Acyclic Nucleoside Phosphonates. H. MERTLÍKOVÁ-KAISEROVÁ, M. NEJEDLÁ, A. HOLÝ, I. VOTRUBA (<i>Prague, Czech Republic</i>)	497
Expression Profiles of Signal Transduction Genes in <i>Ex Vivo</i> Drug-resistant Pediatric Acute Lymphoblastic Leukemia. J. SZCZEPANEK, M. POGORZALA, M. JARZAB, M. OCZKO-WOJCIECHOWSKA, M. KOWALSKA, A. TRETYN, M. WYSOCKI, B. JARZAB, J. STYCZYNSKI (<i>Bydgoszcz; Torun; Gliwice, Poland</i>)	503
Putative Supramolecular Complexes Formed by Carotenoids and Xanthophylls with Ascorbic Acid to Reverse Multidrug Resistance in Cancer Cells. J. MOLNÁR, J. SERLY, R. PUSZTAI, I. VINCZE, P. MOLNÁR, G. HORVÁTH, J. DELI, T. MAOKA, A. ZALATNAI, H. TOKUDA, H. NISHINO (<i>Szeged; Pécs; Budapest, Hungary; Kyoto; Kanazawa, Kusatu, Japan</i>)	507
Cytotoxicity of Hydrophilic Silver Carboxylato Complexes. E. FOURIE, E. ERASMUS, J.C. SWARTS, A. TUCHSCHERER, A. JAKOB, H. LANG, G.K. JOONE, C.E.J. VAN RENSBURG (<i>Bloemfontein; Pretoria, Republic of South Africa; Chemnitz, Germany</i>)	519
P53 Mutation and LOH at Chromosome 9 in Urothelial Carcinoma. T. BEOTHE, A. NAGY, L. FARKAS, G. KOVACS (<i>Heidelberg, Germany; Pécs, Hungary</i>)	523
<i>Clinical Studies</i>	
Oral Metronomic Cyclophosphamide with and without Methotrexate as Palliative Treatment for Patients with Metastatic Breast Carcinoma. V. GEBBIA, H. BOUSSEN, M.R. VALERIO (<i>Palermo, Italy; Tunis, Tunisia</i>)	529
The Evaluation of E-Cadherin and Vimentin as Biomarkers of Clinical Outcomes Among Patients with Non-small Cell Lung Cancer Treated with Erlotinib as Second- or Third-line Therapy. F. RICHARDSON, G.D. YOUNG, R. SENNELLO, J. WOLF, G.M. ARGAST, P. MERCADO, A. DAVIES, D.M. EPSTEIN, B. WACKER (<i>Farmingdale, NY; Flagstaff, AZ; Boulder, CO, USA</i>)	537